tiprankstipranks
Advertisement
Advertisement
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy
PremiumCompany AnnouncementsRAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy
3M ago
Rapport Therapeutics price target raised to $65 from $53 at BTIG
Premium
The Fly
Rapport Therapeutics price target raised to $65 from $53 at BTIG
3M ago
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
Premium
Ratings
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
3M ago
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
PremiumCompany AnnouncementsRapport Therapeutics advances RAP-219 after strong Phase 2a data
4M ago
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
Premium
The Fly
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
4M ago
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100